Effect of Transdermal Nicotine Delivery as an Adjunct to Low-Intervention Smoking Cessation Therapy

A Randomized, Placebo-Controlled, Double-blind Study

David M. Daughton, Scott A. Heatley, John J. Prendergast, Donna Causey, Mark Knowles, Clyde N. Rolf, Ron A. Cheney, Kathleen Hatlelid, Austin Bassett Thompson, Stephen I. Rennard

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

To assess the smoking cessation efficacy of transdermal nicotine patches as an adjunct to low-intervention therapy, we conducted a double-blind, placebo-controlled trial in 158 smokers. Participants were randomly assigned to one of the following three study regimens that required daily application of two 15cm2 patches: (1) 24-hour nicotine delivery, (2) nicotine delivery during wakeful hours only, and (3) placebo. The impact of the three regimens on smoking cessation rates and tobacco withdrawal symptoms was examined. During the last 2 weeks of the trial, 39% of the 24-hour nicotine regimen delivery group, 35% of those on wakeful hour nicotine regimens, and 13.5% of the placebo treatment group achieved abstinence. Self-reported quit rates for the two nicotine patch-wearing regimens, as compared with that for the placebo group, continued to be significantly higher at 6 months. Moreover, compared with placebo, the transdermal nicotine patches significantly reduced tobacco withdrawal symptoms during the first few weeks of quitting. The differences in quit rates and tobacco withdrawal symptoms between the two active groups were not statistically significant. The patches were well tolerated both topically and systemically. We concluded that transdermal nicotine, when used as an adjunct to low-intervention therapy, significantly reduced tobacco withdrawal symptoms and enhanced smoking cessation rates.

Original languageEnglish (US)
Pages (from-to)749-752
Number of pages4
JournalArchives of Internal Medicine
Volume151
Issue number4
DOIs
StatePublished - Jan 1 1991

Fingerprint

Smoking Cessation
Nicotine
Substance Withdrawal Syndrome
Double-Blind Method
Tobacco Use Cessation Products
Placebos
Tobacco
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Effect of Transdermal Nicotine Delivery as an Adjunct to Low-Intervention Smoking Cessation Therapy : A Randomized, Placebo-Controlled, Double-blind Study. / Daughton, David M.; Heatley, Scott A.; Prendergast, John J.; Causey, Donna; Knowles, Mark; Rolf, Clyde N.; Cheney, Ron A.; Hatlelid, Kathleen; Thompson, Austin Bassett; Rennard, Stephen I.

In: Archives of Internal Medicine, Vol. 151, No. 4, 01.01.1991, p. 749-752.

Research output: Contribution to journalArticle

Daughton, David M. ; Heatley, Scott A. ; Prendergast, John J. ; Causey, Donna ; Knowles, Mark ; Rolf, Clyde N. ; Cheney, Ron A. ; Hatlelid, Kathleen ; Thompson, Austin Bassett ; Rennard, Stephen I. / Effect of Transdermal Nicotine Delivery as an Adjunct to Low-Intervention Smoking Cessation Therapy : A Randomized, Placebo-Controlled, Double-blind Study. In: Archives of Internal Medicine. 1991 ; Vol. 151, No. 4. pp. 749-752.
@article{7023fcf8ca3d45cebcd2f5725d29f873,
title = "Effect of Transdermal Nicotine Delivery as an Adjunct to Low-Intervention Smoking Cessation Therapy: A Randomized, Placebo-Controlled, Double-blind Study",
abstract = "To assess the smoking cessation efficacy of transdermal nicotine patches as an adjunct to low-intervention therapy, we conducted a double-blind, placebo-controlled trial in 158 smokers. Participants were randomly assigned to one of the following three study regimens that required daily application of two 15cm2 patches: (1) 24-hour nicotine delivery, (2) nicotine delivery during wakeful hours only, and (3) placebo. The impact of the three regimens on smoking cessation rates and tobacco withdrawal symptoms was examined. During the last 2 weeks of the trial, 39{\%} of the 24-hour nicotine regimen delivery group, 35{\%} of those on wakeful hour nicotine regimens, and 13.5{\%} of the placebo treatment group achieved abstinence. Self-reported quit rates for the two nicotine patch-wearing regimens, as compared with that for the placebo group, continued to be significantly higher at 6 months. Moreover, compared with placebo, the transdermal nicotine patches significantly reduced tobacco withdrawal symptoms during the first few weeks of quitting. The differences in quit rates and tobacco withdrawal symptoms between the two active groups were not statistically significant. The patches were well tolerated both topically and systemically. We concluded that transdermal nicotine, when used as an adjunct to low-intervention therapy, significantly reduced tobacco withdrawal symptoms and enhanced smoking cessation rates.",
author = "Daughton, {David M.} and Heatley, {Scott A.} and Prendergast, {John J.} and Donna Causey and Mark Knowles and Rolf, {Clyde N.} and Cheney, {Ron A.} and Kathleen Hatlelid and Thompson, {Austin Bassett} and Rennard, {Stephen I.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1001/archinte.1991.00400040091020",
language = "English (US)",
volume = "151",
pages = "749--752",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Effect of Transdermal Nicotine Delivery as an Adjunct to Low-Intervention Smoking Cessation Therapy

T2 - A Randomized, Placebo-Controlled, Double-blind Study

AU - Daughton, David M.

AU - Heatley, Scott A.

AU - Prendergast, John J.

AU - Causey, Donna

AU - Knowles, Mark

AU - Rolf, Clyde N.

AU - Cheney, Ron A.

AU - Hatlelid, Kathleen

AU - Thompson, Austin Bassett

AU - Rennard, Stephen I.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - To assess the smoking cessation efficacy of transdermal nicotine patches as an adjunct to low-intervention therapy, we conducted a double-blind, placebo-controlled trial in 158 smokers. Participants were randomly assigned to one of the following three study regimens that required daily application of two 15cm2 patches: (1) 24-hour nicotine delivery, (2) nicotine delivery during wakeful hours only, and (3) placebo. The impact of the three regimens on smoking cessation rates and tobacco withdrawal symptoms was examined. During the last 2 weeks of the trial, 39% of the 24-hour nicotine regimen delivery group, 35% of those on wakeful hour nicotine regimens, and 13.5% of the placebo treatment group achieved abstinence. Self-reported quit rates for the two nicotine patch-wearing regimens, as compared with that for the placebo group, continued to be significantly higher at 6 months. Moreover, compared with placebo, the transdermal nicotine patches significantly reduced tobacco withdrawal symptoms during the first few weeks of quitting. The differences in quit rates and tobacco withdrawal symptoms between the two active groups were not statistically significant. The patches were well tolerated both topically and systemically. We concluded that transdermal nicotine, when used as an adjunct to low-intervention therapy, significantly reduced tobacco withdrawal symptoms and enhanced smoking cessation rates.

AB - To assess the smoking cessation efficacy of transdermal nicotine patches as an adjunct to low-intervention therapy, we conducted a double-blind, placebo-controlled trial in 158 smokers. Participants were randomly assigned to one of the following three study regimens that required daily application of two 15cm2 patches: (1) 24-hour nicotine delivery, (2) nicotine delivery during wakeful hours only, and (3) placebo. The impact of the three regimens on smoking cessation rates and tobacco withdrawal symptoms was examined. During the last 2 weeks of the trial, 39% of the 24-hour nicotine regimen delivery group, 35% of those on wakeful hour nicotine regimens, and 13.5% of the placebo treatment group achieved abstinence. Self-reported quit rates for the two nicotine patch-wearing regimens, as compared with that for the placebo group, continued to be significantly higher at 6 months. Moreover, compared with placebo, the transdermal nicotine patches significantly reduced tobacco withdrawal symptoms during the first few weeks of quitting. The differences in quit rates and tobacco withdrawal symptoms between the two active groups were not statistically significant. The patches were well tolerated both topically and systemically. We concluded that transdermal nicotine, when used as an adjunct to low-intervention therapy, significantly reduced tobacco withdrawal symptoms and enhanced smoking cessation rates.

UR - http://www.scopus.com/inward/record.url?scp=0025865647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025865647&partnerID=8YFLogxK

U2 - 10.1001/archinte.1991.00400040091020

DO - 10.1001/archinte.1991.00400040091020

M3 - Article

VL - 151

SP - 749

EP - 752

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 4

ER -